Condition: Myeloproliferative Neoplasms · Sponsor: Incyte Corporation
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| The University of Alabama At Birmingham | Birmingham, Alabama, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center | Fairway, Kansas, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Cornell Medical Center | New York, New York, United States | Recruiting |
| Icahn School of Medicine At Mount Sinai | New York, New York, United States | Recruiting |
| Sloan Kettering Institute For Cancer Research | New York, New York, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| University of Pennsylvania Health System | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06313593